--- a
+++ b/clusters/9knumclustersv2/clust_136.txt
@@ -0,0 +1,89 @@
+Treatment with any investigational agent within  weeks prior to cycle , day , or five drug half-lives (whichever is longer)
+Treatment with any other investigational agent, device, or procedure within  days (or  half-lives, whichever is greater) of enrollment.
+Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within  days or five half-lives of the investigational agent, whichever is longer, prior to enrollment
+Exposure to an investigational product within  days or five half-lives (whichever is the longer) prior to randomization
+Participants may not be receiving any other investigational agents; patients previously treated with investigational agents must complete a washout period of at least two weeks or five half-lives, whichever is longer, before starting treatment
+Patient who has participated in a prior investigational study within  days prior to treatment start or within  half-lives of the investigational product, whichever is longer
+Participants may not have received treatment with another investigational drug or device within  days prior to day , or if the half-life of the previous product is known, within  times the half-life prior to dosing, whichever may be longer
+Investigational therapy (NOTE: or within a time interval less than at least  half-lives of the investigational agent, whichever is longer).
+Investigational therapy administered within  weeks, or within a time interval less than at least  half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
+Participation in a prior investigational study =<  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Participation in any interventional study within  weeks of Cycle  Day  or  half-lives of the investigational agent(s) used in the interventional study prior to Cycle  Day  (whichever is longer).
+Participation in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Participation in another clinical study with an investigational product during the last  days or five half-lives of the drug (whichever is greater) prior to the initiation of study treatment
+Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within  days or  half lives (whichever is longer) of initiating study treatment.
+Participation in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Administration of investigational agents or investigational drugs </= weeks or less than (<) times the terminal half-life prior to study treatment start, whichever is longer
+Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within  weeks or  half-lives (whichever is longer)
+Previously received investigational product in a clinical trial within  days or within  elimination half lives (whichever is longer) prior to the start of study therapy, or is planning to take part in another clinical trial while participating in this study.
+Participants who are currently receiving any other investigational agent or have received an investigational agent within  days or  half-lives prior to study entry, whichever is longer.
+Participation in a prior investigational study within  days prior to treatment or within  half-lives of the investigational product, whichever is longer
+Participation in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Treatment with any investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Participation in another clinical study with an investigational product during the last  months or within five half-lives of the compound, whichever is longer
+Use of an investigational product within  days or  half-lives, whichever is longer, preceding Study Day .
+MEDICATION-RELATED: Treatment with investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer).
+Investigational agent within  weeks prior to start of study treatment (or within five half-lives of the investigational product, whichever is longer).
+Concomitant use of another investigational agent and/or treatment with an investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Participants who are receiving any other investigational agents; patients previously treated with investigational agents must complete a washout period of at least one week or five half-lives, whichever is longer, before starting treatment
+Have participated within the past  days in a clinical trial involving an investigational product. If the previous investigational product has a long half-life,  months or  half-lives (whichever is longer) should have passed.
+Received active treatment on another investigational trial within  days (or  half-lives of that agent, whichever is greater) prior to Screening
+Patients must not have had investigational therapy administered =<  weeks, or within a time interval less than at least  half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
+Treatment with investigational agent within  weeks prior to study treatment (or within five half lives of the investigational product, whichever is longer)
+(Atezolizumab-related exclusion) Treatment with investigational agent within  weeks prior to cycle , day  (or within five half lives of the investigational product, whichever is longer)
+Participation in any other investigational drug study or had exposure to any other investigational agent, device, or procedure, within  days (or  half-lives, whichever is greater)
+Treatment with any investigational drug within  days prior to registration or within  half-lives of the investigational product, whichever is longer.
+Use of other investigational agent at the time of screening, or within  days or five half-lives of screening , whichever is longer
+Participation in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half lives of the investigational product, whichever is longer)
+Participation in another clinical study with an investigational product during the last  days or  half-lives of the investigational product, whichever is longer
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Participation in a prior investigational interventional study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Has received an investigational drug, investigational vaccine, or has used an investigational medical device within  weeks or  half-lives, whichever is longer, before cycle , day  of study therapy
+DONOR: Received any investigational agent within  days and/or  half-lives (of the other investigational agent), whichever is longer, of receiving BL-
+Patient is currently participating or has participated in a study with an investigational compound or device within  days of study day  or within  half-lives of the investigational product, whichever is longer, with the exception of a prior cyclin dependent kinase (CDK) / inhibitor
+Participation in a prior investigational therapeutic study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Exposure to an investigational product within  days or  half lives (whichever is longer) prior to randomisation
+Treatment with an investigational agent within  days of study entry, or  half-lives, whichever is longer
+Patients who are receiving investigational therapies or who have been treated with investigational therapies or investigational devices within  half-lives of the investigational therapy or  weeks of first scheduled day of dosing with PFK- if the half-live of the investigational agent is not known.
+Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within five half-lives of the compound or  months, whichever is greater
+Treatment with another investigational drug, biological agent, or device within  months of screening, or  half-lives of the study agent, whichever is longer.
+Use of an investigational product (IP) within  days or  half-lives, whichever is longer, preceding Study Day .
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half lives of the investigational product, whichever is longer).
+Treatment with any other investigational agent or investigational device within  weeks prior to registration (or within five half-lives of the investigational product, whichever is longer); patients must be >=  weeks since any investigational agent administered as part of a phase  study (also referred to as an early phase I study or pre phase I study where a sub- therapeutic dose of drug is administered) at the coordinating center principal investigator (PI)s discretion, and should have recovered to eligibility levels from any toxicities
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Any investigational agent within  days or  half-lives prior to enrollment, whichever is longer.
+participants who are currently receiving any other investigational agent or have received an investigational agent within  days or  half-lives, whichever is longer, prior to study entry
+Participation in another clinical study with an investigational product during the last  days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment ( weeks for nitrosoureas or mitomycin C)
+Treatment with any investigational agent within  days (or  serum half-lives of the investigational drug, whichever is longer) of enrollment
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Participation in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Other investigational study agent (any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric) (At least  days or five half-lives, whichever is longer, since last dose prior to the first dose of tazemetostat)
+Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within  weeks or  half-lives (whichever is longer)
+Patient has participated in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer
+Participation in a prior investigational study within  days prior to enrollment or =<  half-lives of the investigational product, whichever is longer
+Exposure to any investigational product within  days or  half lives (whichever is longer) prior to randomisation
+Participation in another interventional clinical study or use of any experimental therapy within  days before initiation of study drug on Day  in this study or within  half-lives of that investigational product, whichever is greater.
+Exposure to another investigational drug within  days of first dosing visit, or  half-lives of the study product (whichever is longer)
+Participation in another interventional clinical study or use of any experimental therapy within  days before initiation of study drug on Day  in this study or within  half-lives of that investigational product, whichever is greater.
+Concomitant use of another investigational agent and/or treatment with an investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Participation in a prior investigational study within  days prior to enrollment or within  half-lives of the investigational product, whichever is longer.
+Any investigational agent =<  days or  half-lives prior to randomization (whichever is longer)
+Subject has received an investigational agent within  weeks or  half lives whichever is longer prior to Day .
+The patient has received any biological therapy ?  days prior to the start of Investigational Product, or monoclonal antibody ?  half-lives or  days, whichever is shorter, prior to the first dose of Investigational Product.
+Exposure to an investigational product within  days or  half lives (whichever is longer) prior to start of the current study drug.
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Use of an investigational agent, including an investigational anti-cancer agent, within  days or  half-lives, whichever is longer, prior to the first dose of study drug
+EXPANSION COHORT ONLY: Use of an investigational agent, including an investigational anti-cancer agent, within  days or  half-lives, whichever is longer, prior to the first dose of study drug
+Patients who have received another investigational product within the longer of  days or  half-lives of the previous product
+Treatment with investigational agent within  weeks prior to cycle , day  (or within five half-lives of the investigational product, whichever is longer)
+Exposure to any investigational product (IP) within  days or  half-lives (whichever is longer) prior to start of study treatment;
+Participation in any other clinical study with a potentially therapeutic agent or receipt of another investigational product within  days or  plasma half-lives, whichever is longer, prior to first day of drug administration (Day ).
+Treatment with investigational agent within  weeks prior to Cycle , Day  (or within five half lives of the investigational product, whichever is longer)
+Treatment with an investigational drug within  days or  half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo)
+Patient has participated in any interventional clinical trial for an aGVHD therapeutic agent or for an immunomodulatory drug, within the past  days or within  half-lives of the investigational medicinal product (IMP), whichever is the greater.
+<  half-lives or  days, whichever is longer, for any investigational agent (for any indication)
+Receipt of any investigational product within  days prior to study drug administration or  half-lives, whichever is longer.
+The subject has received an investigational product within the following time period prior to the first dosing day in the current study:  days or  half-lives or twice the duration of the biological effect of the investigational product (whichever is warranted by the data).
+Treatment with another investigational drug or device within  days prior to day , or if the half-life of the previous product is known, within  times the half-life of the investigational drug prior to dosing, whichever is longer
+Exposure to investigational drug (including investigational vaccines) or invasive investigational medical device for any indication within  weeks or  half-lives, whichever is longer, before Cycle , Day